G
Glenn M. Chertow
Researcher at Stanford University
Publications - 830
Citations - 94517
Glenn M. Chertow is an academic researcher from Stanford University. The author has contributed to research in topics: Kidney disease & Dialysis. The author has an hindex of 128, co-authored 764 publications receiving 82401 citations. Previous affiliations of Glenn M. Chertow include University of Groningen & Fresenius Medical Care.
Papers
More filters
Journal ArticleDOI
Low level of self-reported physical activity in ambulatory patients new to dialysis
Kirsten L. Johansen,Kirsten L. Johansen,Glenn M. Chertow,Nancy G. Kutner,Lorien S. Dalrymple,Barbara Grimes,George A. Kaysen,George A. Kaysen +7 more
TL;DR: Physical activity was found to be extremely low with scores for all age and gender categories below the 5th percentile of healthy individuals and 95% of patients had scores consonant with low fitness.
Journal ArticleDOI
Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial
Sharon M. Moe,Safa Abdalla,Glenn M. Chertow,Patrick S. Parfrey,Geoffrey A. Block,Ricardo Correa-Rotter,Jürgen Floege,Charles A. Herzog,Gérard M. London,Kenneth W. Mahaffey,David C. Wheeler,Bastian Dehmel,William G. Goodman,Tilman B. Drüeke +13 more
TL;DR: It is found that when accounting for differences in baseline characteristics, multiple fractures, and/or events prompting discontinuation of study drug, cinacalcet reduced the rate of clinical fracture by 16%-29%.
Journal ArticleDOI
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): Rationale and Design Overview
Glenn M. Chertow,Lara B. Pupim,Geoffrey A. Block,Ricardo Correa-Rotter,Tilman B. Drüeke,Jürgen Floege,William G. Goodman,William G. Goodman,Gérard M. London,Kenneth W. Mahaffey,Sharon M. Moe,David C. Wheeler,Moetaz Albizem,Kurt Olson,Preston S. Klassen,Patrick S. Parfrey +15 more
TL;DR: Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events will determine whether management of secondary hyperparathyroidism with cinacAlcet reduces the risk for mortality and cardiovascular events in hemodialysis patients.
Journal ArticleDOI
Association of Fetuin-A With Mitral Annular Calcification and Aortic Stenosis Among Persons With Coronary Heart Disease Data From the Heart and Soul Study
Joachim H. Ix,Glenn M. Chertow,Michael G. Shlipak,Vincent Brandenburg,Markus Ketteler,Mary A. Whooley +5 more
TL;DR: An inverse association was observed between fetuin-A and aortic stenosis among participants without diabetes mellitus and may represent an important inhibitor of dystrophic calcification in persons with coronary heart disease.
Journal ArticleDOI
Survival after acute myocardial infarction in patients with end-stage renal disease: results from the cooperative cardiovascular project.
TL;DR: In light of the exceptionally poor outcomes observed for patients treated with medical therapy alone, it may be premature to dismiss PTCA as a therapeutic option in this population of patients with end-stage renal disease.